



Kilitch Drugs (India) Ltd.

December 18, 2020

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To,
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Dear Sirs,

Sub.: Disclosure Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

As informed earlier, KILITCH has already set up its second green field project in Ethiopia under name of Kilitch Estro Biotech PLC, Ethiopia, a foreign subsidiary of the Company, at Oromia Special Zone, Ethiopia, on invitation of Ethiopian Government.

We are delighted to share that aforesaid subsidiary Company has received the Manufacturing License to produce "**Cephalosporin**" Dry Powder Injections / Tablets / Capsules & Dry syrup at Kilitch Estro Biotech PLC, Addis Ababa, Ethiopia w.e.f. December 18, 2020.

We have setup the state of art dedicated Cephalosporin facility and production of the same will commence soon. This facility will help us to address the immense prospects in Ethiopian local market and African continent.

Grant of manufacturing license is a stepping stone for Kilitch foray in Africa & this expansion would ensure volume growth and better profitability in coming years ahead.

The above is for information and dissemination to the public at large.

Thanking You,
Yours Faithfully

For Kilitch Drugs (India) Limited

Mukund Mehta
Managing Director
DIN: 00147876

